过敏原特异性免疫治疗改善特应性皮炎临床与免疫指标
该研究纳入14例轻中度特应性皮炎伴尘螨过敏性鼻炎患者,其中8例随机接受辅助过敏原免疫治疗(AIT)。6个月后,AIT组临床参数和屏障功能显著改善,过敏原斑贴试验转阴,皮肤树突状细胞和T细胞募集减少,但血清和皮肤IgE及点刺试验无显著变化。结论认为AIT是有益的辅助治疗,其效果应通过过敏原斑贴试验而非点刺试验检测。
要点
- AIT辅助治疗可显著改善轻中度AD患者的临床症状和皮肤屏障功能。
- AIT后过敏原斑贴试验转阴,皮肤树突状细胞和T细胞募集显著减少。
- AIT对致敏状态的影响应通过过敏原斑贴试验而非点刺试验评估。
核心结论
- 过敏原免疫治疗是致敏AD患者的有益辅助治疗,可改善临床症状和通透性屏障功能。
- AIT对致敏状态的影响应通过过敏原斑贴试验检测,而非点刺试验。
研究设计与样本
- 研究纳入14例轻中度AD伴尘螨过敏性鼻炎患者,所有患者接受局部治疗,其中8例随机选择接受辅助AIT。
- 在基线和6个月后,进行临床、屏障和免疫学检查(血清和皮肤测试),并对部分患者的过敏原斑贴试验活检组织进行免疫组化分析。
主要发现
- 在辅助AIT组,临床参数和屏障功能显著改善。
- 血液免疫参数无显著变化。
- AIT组所有患者治疗后过敏原斑贴试验转阴,而非AIT组仍为阳性。
- AIT组过敏原激发后皮肤树突状细胞和T细胞募集显著减少。
- 皮肤或血清IgE水平及点刺试验反应性无显著变化。
临床怎么用
- 对于伴有尘螨过敏性鼻炎的轻中度AD患者,可考虑AIT作为辅助治疗以改善临床症状和屏障功能。
- 评估AIT对致敏状态的效果时,应优先采用过敏原斑贴试验而非点刺试验。
局限性
- 样本量较小(n=14),可能影响结果的普遍性。
- 研究期限为6个月,长期疗效未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Allergen immunotherapy (AIT) is considered a curative treatment in some atopic diseases, but in AD contradictory clinical results exist and the action of AIT has not been elucidated. In the literature, there is no evidence for parallel investigations of permeability barrier, cutaneous and blood immune responses after AIT in AD. OBJECTIVES: The objective was to investigate immune parameters in the blood and skin and to detect clinical and barrier changes after AIT in AD. METHODS: Mild-to-moderate AD patients (n = 14) with concomitant allergic rhinitis to house dust mites were selected. All patients received topical treatment, while eight patients were randomly selected for adjuvant AIT also. At baseline and after 6 months, clinical, barrier and immunological investigations (serum and skin tests) were performed. In selected patients, biopsies from atopy patch tests (APTs) were analysed by immunohistochemistry for AD-relevant immune cells and mediators. RESULTS: In the adjuvant AIT group, clinical parameters and barrier functions improved significantly. Blood immune parameters displayed no significant changes. Post-AIT APT became negative in all patients in the AIT group, but remained positive in the non-AIT group. Cutaneous dendritic cell and T-cell recruitment decreased significantly after allergen challenge in the AIT group, but no significant changes in skin or serum immunoglobulin E levels or prick test (SPT) reactivity were detected. CONCLUSIONS: Allergen immunotherapy is a beneficial adjuvant treatment for sensitized AD patients. AIT improves not only clinical symptoms, but also permeability barrier functions. The effect of AIT on sensitization should be detected by APT, not by SPT.
引用
- Hajdu K, Kapitány A, Dajnoki Z, et al. Improvement of clinical and immunological parameters after allergen-specific immunotherapy in atopic dermatitis. J Eur Acad Dermatol Venereol. 2020. PMID: 33131126. doi:10.1111/jdv.17018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。